Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India

Shanmugam Saravanan, Vidya Madhavan, Pachamuthu Balakrishnan, Davey M. Smith, Sunil Suhas Solomon, Sathasivam Sivamalar, Selvamuthu Poongulali, Nagalingeswaran Kumarasamy, Robert T. Schooley, Suniti Solomon, Rami Kantor

Research output: Contribution to journalArticlepeer-review

Abstract

Eleven protease mutations have been associated with reduced susceptibility to darunavir. In this study of 87 HIV-1-infected patients experiencing virological failure to second-line regimens containing protease inhibitors boosted with ritonavir (viral load >1,000 HIV RNA copies/ml), we observed a low prevalence (3%) of ≥3 darunavir resistance-Associated mutations, indicating that this drug may be a good option for third-line antiretroviral therapy in southern India.

Original languageEnglish (US)
Pages (from-to)630-632
Number of pages3
JournalAIDS research and human retroviruses
Volume29
Issue number3
DOIs
StatePublished - Mar 1 2013
Externally publishedYes

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Darunavir is a good third-line antiretroviral agent for HIV type 1-infected patients failing second-line protease inhibitor-based regimens in South India'. Together they form a unique fingerprint.

Cite this